Results - Announcements
Zim Laboratories Ltd share price dropped 5.28% to Rs 134.6 after the company's net profit tumbled by 49% to Rs 2.05 crore, while revenue from operations edged up 11.97% to Rs 105.45 crore in Q3FY26 over Q2FY26.
The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.73 lakh crore, gaining 4.51%. It has inched up 2.58% over last one week and gained upto 2.10% in last one month while the market capitalization of Zim Laboratories Ltd has slipped by 5.08% and 17.30% in the same period respectively.
Profit before tax (PBT) of Zim Laboratories Ltd stood at Rs 2.74 crore in Q3 FY26, jumping 705.88% year-on-year, and plunging by 50.81% quarter-on-quarter. EBITDA came in at Rs 3 crore, tanking 15.63% YoY and expanding by 114.38% sequentially.
Total expenses grew marginally by 9.73% to Rs 106.55 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 40.84 crore, easing 6.80% YoY, while employee benefits expense was at Rs 19.59 crore, inching up 2.14% YoY.
For the TTM ended FY26, revenue from operations softened by 1.22% to Rs 374.4 crore, while net profit tanked by 52.01% to Rs 5.84 crore, compared to previous TTM. EBITDA surged by 3681% to Rs 18.63 crore, and PBT collapsed by 54.41% to Rs 8.21 crore compared to previous TTM.
The company's consolidated net cash flow from operating activities stood at Rs 49.53 crore in FY26, as against Rs 41.15 crore in FY25.
Zim Laboratories Ltd jumped 94.52% in last one year, significantly outperforming the benchmark BSE Sensex which has softened by 8.41% during the same period.